Title |
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
|
---|---|
Published in |
American Journal of Neuroradiology, March 2008
|
DOI | 10.3174/ajnr.a0928 |
Pubmed ID | |
Authors |
W S Bartynski |
Abstract |
Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state coupled with a unique CT or MR imaging appearance. Recognized in the setting of a number of complex conditions (preeclampsia/eclampsia, allogeneic bone marrow transplantation, organ transplantation, autoimmune disease and high dose chemotherapy) the imaging, clinical and laboratory features of this toxic state are becoming better elucidated. This review summarizes the basic and advanced imaging features of PRES, along with pertinent features of the clinical and laboratory presentation and available histopathology. Many common imaging/clinical/laboratory observations are present among these patients, despite the perception of widely different associated clinical conditions. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Argentina | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 2% |
Brazil | 4 | <1% |
Germany | 3 | <1% |
Japan | 3 | <1% |
India | 2 | <1% |
United Kingdom | 2 | <1% |
South Africa | 2 | <1% |
Spain | 1 | <1% |
Switzerland | 1 | <1% |
Other | 2 | <1% |
Unknown | 551 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 99 | 17% |
Researcher | 84 | 14% |
Student > Postgraduate | 79 | 14% |
Student > Doctoral Student | 52 | 9% |
Professor > Associate Professor | 48 | 8% |
Other | 143 | 25% |
Unknown | 76 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 407 | 70% |
Neuroscience | 21 | 4% |
Unspecified | 14 | 2% |
Agricultural and Biological Sciences | 12 | 2% |
Psychology | 7 | 1% |
Other | 28 | 5% |
Unknown | 92 | 16% |